Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thermal Ablation with Apatinib and Camrelizumab in Advanced Liver Cancer
NCT04204577Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04204577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04204577.